Suivre
Abonner TauRx Therapeutics

TauRx Therapeutics

Filtre
  • 19.05.2020 – 13:00

    TauRx Reveals Study Results That Offers New Hope for Treatment of Patients With Dementia

    Aberdeen, Scotland and Singapore (ots/PRNewswire) - Minimum dose of hydromethylthionine could slow clinical decline and brain atrophy in behavioural variant Fronto-Temporal Dementia as well as Alzheimer's Disease In a paper published online in the Journal of Alzheimer's Disease ( https://doi.org/10.3233/JAD-191173 ) , TauRx reported that the drug it is developing for ...

  • 27.07.2016 – 14:01

    TauRx Reports First Phase 3 Results for LMTX®

    Aberdeen, Scotland and Singapore (ots/PRNewswire) - Promising Read-Out for First-Ever Tau Aggregation Inhibitor to Enter Phase 3 Trials - LMTX® as monotherapy demonstrates significant reductions in disease progression in mild and moderate Alzheimer's disease - Strong results in both cognitive and functional tests supported by brain scan evidence of slow-down in progression of pathology - Study misses co-primary endpoints ...

  • 10.09.2012 – 08:02

    Phase 3 Clinical Trial Begins in Early Form of Dementia

    Manchester, England (ots/PRNewswire) - Investigational drug study follows earlier study with promising results in mild to moderate Alzheimer's patients TauRx Therapeutics today announced the initiation of a global Phase 3 clinical trial in a type of Frontotemporal Dementia (FTD) also known as Pick's Disease. The announcement, which immediately follows The 8th International Conference on Frontotemporal Dementias, held 5-7 ...